

# Lasmiditan (REYVOW)

## Criteria for Use

### April 2024

#### VA Pharmacy Benefits Management Services and National Formulary Committee

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTERnet](#) or [PBM INTRANet](#) site for further information.

## Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive lasmiditan.

- Concurrent therapy with a P-glycoprotein substrates sensitive to minor changes in plasma concentration (e.g. digoxin)
- Concurrent therapy with ubrogepant or rimegepant
- Concurrent therapy with a triptan agent once lasmiditan is initiated
- Pregnancy
- Patient unable to comply with not engaging in activities requiring mental alertness (e.g. driving) for at least 8 hours after taking lasmiditan

## Inclusion Criteria

The answers to all of the following must be fulfilled in order to meet criteria.

- Treatment initiated by a VA/VA Community Care neurologist or locally designated headache expert
- Diagnosis of migraine, with or without aura, per the International Classification of Headache Disorders (ICHD-3)
- Moderate to severe migraine intensity
- Contraindication<sup>1</sup>, intolerance, or lack of response to trial of two different triptans

## Footnotes

1. Vascular contraindications to all triptans include ischemic coronary artery disease, previous stroke or transient ischemic attack, peripheral vascular disease, ischemic bowel disease, or uncontrolled hypertension. Other contraindications with triptans may be drug interaction related such as concurrent use of a MAO inhibitor.